Autoimmune disease

#Autoimmune disease #Biotechnology #Inflammatory diseases

Laigo Bio announces new CSO as part of board appointments 

Biotechnology company Laigo Bio has appointed Dr Richard Sainson as Chief Scientific Officer as part of a swathe of board appointments.  The company, which specialises in autoimmune and inflammatory diseases, says Sainson will lead scientific strategy and oversee the advancement of Laigo’s proprietary SureTACs platform and programmes towards the clinic.   Sainson has over 25… Read More

#News

T cells
#Autoimmune disease #Gilead Sciences #Mergers and acquisitions #T cell engagers

Gilead to advance first T cell engager for autoimmune diseases

Gilead Sciences has entered an agreement to acquire Ouro Medicines, a biotechnology company focused on developing T cell engager therapies for autoimmune diseases.  The acquisition adds OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell engager, to Gilead’s inflammation portfolio.   OM336 is designed to enable rapid and deep B cell depletion following… Read More

#Business & Investment #News

#Autoimmune disease #Biotech #Immunotherapy

Commit Biologics appoints CEO, advances therapeutics pipeline 

Biotechnology company Commit Biologics has appointed Thomas Montgomery Andresen as CEO as it aims to take its complement-powered immune engagers into clinic.  Commit described Andresen as “a serial biotech entrepreneur”, with over 20 years of experience building high-value biotech ventures at the intersection of therapeutic innovation and bioengineering.  … Read More

#News

#Autoimmune disease #Drug discovery #Infectious diseases

Asahi Kasei Pharma strengthens drug discovery pipeline 

Asahi Kasei Pharma has announced a global license agreement with Alchemedicine to strengthen its drug discovery pipeline.  The agreement means Asahi Kasei Pharma can research, develop, manufacture, and commercialise Alchemedicine’s novel lead compounds, which are currently at the preclinical stage.  The compounds were identified using Alchemedicine’s drug discovery platform, HiSAP1 and are expected to have therapeutic potential for multiple… Read More

#Business & Investment #News

Biochemists working in the lab
#Artificial intelligence (AI) #Autoimmune disease #CNS #Collaboration #Insilico Medicine

Insilico and CMS announce CNS and autoimmune collaboration

Insilico Medicine and China Medical System (CMS) have announced a series of AI‑empowered drug discovery collaborations in the fields of central nervous system and autoimmune diseases.  According to the collaboration agreement, the parties will combine Insilico Medicine's AI-enabled drug discovery and development capabilities with CMS's experienced R&D team and disease-area… Read More

#Business & Investment #News

#Advanced Therapies #Autoimmune disease #Cell therapy #Eli Lilly #Orna Therapeutics

Lilly to advance cell therapies after Orna acquisition 

Eli Lilly has acquired biotech company Orna Therapeutics to further develop its pipeline of cell therapies in autoimmune diseases.  Orna is advancing a new class of therapeutics utilising engineered circular RNA paired with novel lipid nanoparticles to allow the patient’s own body to generate cell therapies that can treat underlying disease.  The company’s lead programme,… Read More

#Business & Investment #News

Metabolomics
#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Precision medicine #Webinar

Uncover novel biomarkers using metabolomic and lipidomic profiling

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

Monoclonal antibody
#Acute inflammatory conditions #Autoimmune disease #Clinical trial #Monoclonal antibodies

Nucleome to develop first-in-class monoclonal antibody 

Biotechnology company Nucleome Therapeutics is set to advance a potential first-in-class treatment for major chronic inflammatory diseases.  NTP464 is a potential first-in-class monoclonal antibody agonist with strong potency, selectivity and developability characteristics. Nucleome has nominated NTP646 for development.  The target of NTP464 is a novel inflammation checkpoint identified using Nucleome’s proprietary suite of… Read More

#News

#Acute inflammatory conditions #Autoimmune disease #Bispecific Antibodies #Collaboration #Earendil Labs #Sanofi

Sanofi and Earendil agree $2.56b bispecific antibodies deal

Earendil Labs and Sanofi have agreed a strategic collaboration to apply Earendil's discovery platform to multiple autoimmune and inflammatory disease programmes.  Sanofi will lead the development and worldwide commercialisation of bispecific candidates arising from the collaboration.  According to the agreement Earendil Labs will receive up to $160 million in upfront… Read More

#Business & Investment #News

#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Precision medicine #Webinar

Webinar: The importance of untargeted approaches to discovery

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Precision medicine #Webinar

Webinar: Discover untargeted metabolomics and lipidomics approaches

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

Biomarkers concept
#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Precision medicine #Webinar

Webinar: Accelerate your research in complex biological systems

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

Metabolomics
#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Webinar

Webinar: Leveraging untargeted metabolomics and lipidomics

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

Metabolomics
#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Webinar

Unbiased exploration of biological systems: Leveraging untargeted metabolomics and lipidomics for drug discovery

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar will begin with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#Webinars

#Autoimmune disease #Monte Rosa Therapeutics #Preclinical development

Monte Rosa announces results for autoimmune disease treatment 

Biotechnology company Monte Rosa Therapeutics has released preclinical data on MRT-6160, a molecular glue degrader (MGD) to treat autoimmune and inflammatory diseases.  The findings reveal MRT-6160, a first-in-class VAV1-directed MGD, inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly in a spontaneous autoimmune… Read More

#News

CAR-T therapy
#Autoimmune disease #Bristol Myers Squibb #CAR-T #Cell therapy #Lupus

BMS’s CAR-T shows potential for immune reset in lupus

Bristol Myers Squibb has shared its first results in chronic, refractory autoimmune diseases from the Phase I Breakfree-1 study of its investigational, autologous CD19-targeted NEX-T CAR T cell therapy BMS-986353 (CC-97540).   The data evaluates a total of 71 treated patients across the systemic sclerosis (SSc), systemic lupus… Read More

#Editor's Choice #News